Olverembatinib (HQP-1351)

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search

Mechanism of action

Third-generation TKI

Diseases for which it is used

History of changes in NMPA indication

  • 2021-11: Initial conditional approval for the treatment of adult patients with TKI-resistant CML-CP or CML-AP harboring the T315I mutation as confirmed by a validated diagnostic test. (Based on HQP1351CC203)

Also known as

  • Code name: HQP-1351